Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that the Company has granted a total of 3,261,577 options to purchase ordinary shares of 1 pence each of Motif Bio.
Pete A. Meyers, Chief Financial Officer, has been granted 2,961,577 options to purchase Ordinary Shares which vest over a four year period and are partially based on meeting certain performance targets. Rajesh B. Shukla Ph.D., Vice President of Clinical Operations, was granted 300,000 options to purchase Ordinary Shares which vest over a four year period. The options have an exercise price of 40.50 pence per Ordinary Share, being the closing price of the Ordinary Shares on 21 April 2016, the date of grant of the options.
